LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Amgen Inc

Затворен

СекторЗдравеопазване

290.17 1.13

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

287.07

Максимум

292.94

Ключови измерители

By Trading Economics

Приходи

1.1B

1.7B

Продажби

-937M

8.1B

P/E

Средно за сектора

26.32

51.198

EPS

4.9

Дивидентна доходност

3.3

Марж на печалбата

21.23

Служители

28,000

EBITDA

-1.7B

1.2B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+13.61% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.30%

2.40%

Следващи печалби

5.08.2025 г.

Следваща дата на дивидент

5.09.2025 г.

Следваща дата на екс-дивидент

15.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-3B

155B

Предишно отваряне

289.04

Предишно затваряне

290.17

Настроения в новините

By Acuity

39%

61%

126 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Amgen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.05.2025 г., 20:17 ч. UTC

Печалби

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New -2-

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19.05.2025 г., 16:13 ч. UTC

Придобивния, сливания и поглъщания

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen: FY25 Share Repurchases Not to Exceed $500M

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen Sees FY25 Capital Expenditures About $2.3B

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Repatha Sales $656M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q EVENITY Sales $442M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Net $1.73B >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Adj EPS $4.90 >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q EPS $3.20 >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Rev $8.15B >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Rev $8.1B >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Net $1.73B >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen 1Q EPS $3.20 >AMGN

1.05.2025 г., 20:01 ч. UTC

Печалби

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

Сравнение с други в отрасъла

Ценова промяна

Amgen Inc Прогноза

Ценова цел

By TipRanks

13.61% нагоре

12-месечна прогноза

Среден 326.18 USD  13.61%

Висок 400 USD

Нисък 252 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Amgen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

21 ratings

10

Купи

10

Задържане

1

Продай

Техническа оценка

By Trading Central

270.44 / 276.44Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

126 / 380 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.